Treatment Approach for Androgen Receptor–Indifferent Prostate Cancer

Video

This video covers the treatment approach for patients with androgen receptor–indifferent prostate cancer.

In this video, Ana Aparicio, MD, of the University of Texas MD Anderson Cancer Center, discusses the treatment approach for patients with androgen receptor (AR)-indifferent prostate cancer.

AR-indifferent prostate cancer can include patients with small-cell carcinoma or neuroendocrine tumors, which are often AR-negative, but often these are mixed with disease elements that do express the AR.

Recent data suggests these patients are more likely to response to platinum-based chemotherapy such as carboplatin.

Aparicio gave a presentation on this topic at the 2017 Genitourinary Cancers Symposium in Orlando, Florida.

Recent Videos
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content